Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ...

Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently ...

Under this transaction, Organovo will receive an upfront payment as well as milestones to be paid as FXR314 achieves key regulatory and commercial milestones. Lilly is acquiring all commercial and ...

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...

FXR Pro Fish, a brand driven by bringing innovation to the water, is proud to announce its partnership with the Bassmaster ...

Detailed price information for Indust/Producer Dur Alphadex ETF FT (FXR-A) from The Globe and Mail including charting and trades.

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will ...

FXR Pro Fish, a brand driven by bringing innovation to the water, is proud to announce its partnership with the Bassmaster Elite series as the title sponsor for the first round of the new season.